《大行报告》瑞银上调友邦(01299.HK)目标价至118元 指首季业绩远胜预期
瑞银发表报告表示,友邦保险(01299.HK)公布今年首季新业务价值按实质汇率计升25%,按固定汇率计则升19%,显示3月份呈快速增长,令公司首季表现远胜预期,相信是产品销量增长(年化新保费升15%)及毛利率(由56.5%升至61.6%)扩大所推动,确认该行对其毛利复苏预期的观点。
该行指,重申对友邦保险「买入」投资评级,上调目标价由115元升至118元,决定调高对公司2021年新业务价值按实质汇率计(AER)增长预测3%至28%((按固定汇率计则料升24%)。
瑞银表示,友邦首季新业务价值强劲,受惠於旗下主要市场特别是中国内地、泰国、马来西亚及本港本地业务等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.